NCT01419262

Brief Summary

Vitamin D can be made in the skin by exposure to sunlight and can be found in certain foods. Vitamin D levels are alarmingly low in many North American children. Several health issues have been linked with low vitamin D. These include colds caused by viruses and asthma attacks. However, no study has determined whether vitamin D supplementation can reduce the risk of these conditions in young children where they are most common and most severe. The goals of this study are to determine whether wintertime high dose vitamin D supplementation of preschoolers can prevent colds and asthma attacks. The investigators also aim to work out how much money would be saved by the health care system and society if preschoolers were routinely supplemented with Vitamin D during the winter. The investigators believe that preschoolers receiving 'high dose' vitamin D supplementation during the wintertime will be less likely to have colds, asthma attacks, and low vitamin D levels and will be less likely to use the medical system and keep their parents away from work.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
703

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Sep 2011

Typical duration for phase_3

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 18, 2011

Completed
14 days until next milestone

Study Start

First participant enrolled

September 1, 2011

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

June 14, 2019

Status Verified

June 1, 2019

Enrollment Period

3.7 years

First QC Date

August 16, 2011

Last Update Submit

June 11, 2019

Conditions

Keywords

Vitamin DRandomized Controlled TrialChild, PreschoolDietary SupplementsRespiratory Tract InfectionsAsthma

Outcome Measures

Primary Outcomes (1)

  • Number of Laboratory confirmed upper respiratory tract infections

    Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Reverse transcriptase polymerase chain reaction will be performed on each sample. Samples will be tested for 18 common respiratory viruses using the ID-TagTM RVP assay using the Luminex xMAPTM system.

    Up to 8 months

Secondary Outcomes (4)

  • Number of parent reported upper respiratory tract infections

    Up to 8 months

  • Number of Asthma exacerbations

    Up to 8 months

  • Serum vitamin D level

    5-8months

  • Direct and indirect economic costs associated with upper respiratory tract infections

    16 months

Other Outcomes (3)

  • Body Mass index z-score

    Up to 8 months

  • Waist circumference z-score

    Up to 8 months

  • Serum Lipids

    Up to 8 months

Study Arms (2)

2000 IU per day vitamin D

EXPERIMENTAL
Drug: Vitamin D3 - Cholecalciferol 2000 IU

400 IU per day vitamin D

ACTIVE COMPARATOR
Drug: Vitamin D - Cholecalciferol 400 IU

Interventions

One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up

Also known as: Baby Ddrops, Health Canada NPN #80001869
400 IU per day vitamin D

One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up

Also known as: Ddrops 2000 IU
2000 IU per day vitamin D

Eligibility Criteria

Age1 Year - 5 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Healthy children by parental report
  • Have reached their 1st birthday but not past their 6th birthday
  • Present to a TARGet Kids! practice for routine primary healthcare prior to viral season (September through November)
  • Parents provide informed consent to participate.

You may not qualify if:

  • Children with gestational age \< 32 weeks
  • Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection
  • Children with a sibling participating in the study to reduce clustering effects.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

St. Michael's Hospital

Toronto, Ontario, M5B 1W8, Canada

Location

Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada

Location

Related Publications (2)

  • Huey SL, Acharya N, Silver A, Sheni R, Yu EA, Pena-Rosas JP, Mehta S. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD012875. doi: 10.1002/14651858.CD012875.pub2.

  • Aglipay M, Birken CS, Parkin PC, Loeb MB, Thorpe K, Chen Y, Laupacis A, Mamdani M, Macarthur C, Hoch JS, Mazzulli T, Maguire JL; TARGet Kids! Collaboration. Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA. 2017 Jul 18;318(3):245-254. doi: 10.1001/jama.2017.8708.

MeSH Terms

Conditions

Respiratory Tract InfectionsAsthmaAvitaminosis

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

InfectionsRespiratory Tract DiseasesBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Jonathon L Maguire, MD, MSc

    St. Michael's Hospital, Toronto, Ontario, Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician/ Principal Investigator

Study Record Dates

First Submitted

August 16, 2011

First Posted

August 18, 2011

Study Start

September 1, 2011

Primary Completion

May 1, 2015

Study Completion

October 1, 2015

Last Updated

June 14, 2019

Record last verified: 2019-06

Locations